Sign In
Buy GTHX
$7.15
+0 (+0%)
At Close: Dec 16, 2024
G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conference
02:15pm, Wednesday, 18'th May 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., May 18, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive Off
G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conference
10:15am, Wednesday, 18'th May 2022
RESEARCH TRIANGLE PARK, N.C., May 18, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1's Chief Executive Officer
G1 Therapeutics, Inc. (GTHX) CEO Jack Bailey on Q1 2022 Results - Earnings Call Transcript
03:10pm, Wednesday, 04'th May 2022
G1 Therapeutics, Inc. (NASDAQ:GTHX ) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants Will Roberts - Head-Corporate Communications Jack Bailey - Chief Executive Officer And
G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates
11:45am, Wednesday, 04'th May 2022 Zacks Investment Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of -16.16% and 19.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights
10:30am, Wednesday, 04'th May 2022 GlobeNewswire Inc.
- Achieved $6.9 Million in Total Revenue in the First Quarter of 2022, Including $5.5 Million in Net Revenue from Sales of COSELA™ (trilaciclib) -
G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates
09:02am, Wednesday, 04'th May 2022
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of -16.16% and 19.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09:30pm, Monday, 02'nd May 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., May 02, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerci
Earnings Preview: G1 Therapeutics (GTHX) Q1 Earnings Expected to Decline
07:03pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: G1 Therapeutics (GTHX) Q1 Earnings Expected to Decline
04:49pm, Wednesday, 27'th Apr 2022
G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
G1 Therapeutics: Needs To Expand Labels And Commercialize Better
01:39pm, Wednesday, 27'th Apr 2022
GTHX has stayed depressed because of lack of successful commercialization. It also needs to expand labels into larger indications.
G1 Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 4, 2022
12:30pm, Thursday, 21'st Apr 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., April 21, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corpo
G1 Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 4, 2022
08:30am, Thursday, 21'st Apr 2022
RESEARCH TRIANGLE PARK, N.C., April 21, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corpora
G1 Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
03:30pm, Wednesday, 06'th Apr 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., April 06, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey and Raj Malik, M.D., G1�
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:15pm, Friday, 01'st Apr 2022 GlobeNewswire Inc.
RESEARCH TRIANGLE PARK, N.C., April 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exer
New Real-World Data Show Potential of Trilaciclib to Reduce the Substantial Burden of Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with Chemotherapy
08:05pm, Thursday, 31'st Mar 2022 GlobeNewswire Inc.
Data being presented at the National Comprehensive Cancer Network (NCCN) 2022 Annual Conference Data being presented at the National Comprehensive Cancer Network (NCCN) 2022 Annual Conference
